Patent intelligence · US
US 11834444
Processes for preparation of soluble guanylate cyclase stimulators
Processes for preparation of soluble guanylate cyclase stimulators
Patent details — US 11834444
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2023
- Expiration
- Nov 30, 2043
- Applicant
- Cyclerion Therapeutics, Inc.
- Claims
- 18
- CPC classes
- A61P, A61P43/00, A61P9/00
Quick answer
US 11834444 (Processes for preparation of soluble guanylate cyclase stimulators) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cyclerion Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P43/00, A61P9/00
More from Cyclerion Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12247025
Processes for preparation of soluble guanylate cyclase stimulators
granted -
US 11731977
SGC stimulators
granted -
US 11690828
Treatment of CNS diseases with sGC stimulators
granted -
US 11572358
Solid forms of an sGC stimulator
granted -
US 11466015
Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
granted -
US 11389449
Treatment of metabolic syndrome with an sGC stimulator
granted -
US 11357777
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
granted
Frequently asked questions
What is US patent 11834444?
US 11834444 (Processes for preparation of soluble guanylate cyclase stimulators) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11834444?
Cyclerion Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 11834444 expire?
Our index shows an expiration date of Nov 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.